HESHAN, China, July 13, 2026 /PRNewswire/ -- Yumeya Furniture, a leading global manufacturer of Commercial Metal Wood Grain Furniture, has officially announced the international release of its M+ Modular Seating System. Engineered specifically for the commercial dining and senior living sectors, the M+ system introduces an agile, component-based inventory model designed to replace traditional finished-goods stocking. By enabling distributors to inventory interchangeable parts rather than fully assembled chairs, Yumeya effectively resolves the long-standing industry conflict between offering rapid shipping times and maintaining low warehouse overhead.
The announcement addresses a critical pressure point for international furniture wholesalers managing volatile ocean freight rates and high industrial storage costs.
Why Quick Ship Is Becoming More Difficult
Winning a hospitality furniture contract usually comes down to one thing: can the distributor guarantee "Quick Ship". At the same time, hotels, restaurants and senior living operators are asking for more customized interiors than ever, which pushes distributors to stock a wider and wider range of finished chairs just to stay in the running.
That approach ties up working capital, eats into warehouse space, and can leave distributors holding chairs nobody wants once a design trend moves on. The M+ system changes the equation by separating the structural frame from the visible, style-defining components. Distributors hold the frames and swap in different backs, seats or finishes once a customer's order is confirmed, so the inventory on the shelf stays useful no matter which way design preferences shift.
One Platform, More Product Choices
M+ Modular Seating System works by standardizing the frame across an entire product line. Distributors keep a set of frames and a set of interchangeable components on hand, then assemble the final chair style once a customer's specifications are locked in.
At launch, M+ Modular Seating covers two segments, restaurant seating and senior living furniture, giving distributors more style options without a matching jump in inventory.
M+ Mars Series (Hospitality and Restaurant Seating): The Mars collection pairs three frame options, side chair, armchair and barstool, with five interchangeable backrest designs: upholstered, an upholstered and HPL hybrid, rattan, High-Pressure Laminate (HPL), and aluminum. That's eight components in total, and distributors can mix them into 15 distinct chair styles to match almost any restaurant concept, allowing distributors to stock ingredients, not finished bulk.
M+ Megrez Series (Senior Living Furniture): The Megrez collection is built around a single set of left and right armrest frames that work across the whole line. Swap just three components, the seat and backrest, and a distributor can assemble a Single Sofa, a High-Back Chair or a Patient Chair from the same frame. For common areas that need bench-style seating, five components (two seats, two backrests, the side frames and a connecting armrest) link together into a heavy-duty, multi-seat lounge unit.
What This Means for Freight and Warehouse Costs
For distributors moving product internationally, the real payoff shows up in logistics costs. Knock-down components pack far more tightly than pre-assembled chairs, which means a single container or a single warehouse rack holds a lot more product.
Yumeya ran the numbers using its Olean Seating line as a reference point, and the difference is significant:
| Packaging & Shipping Metrics | Traditional Assembled Mode | M+ Modular KD Mode | Logistical Efficiency Gain |
| Packaging Density | 1 chair per carton | 5 chairs per carton | 5x density increase |
| Volume per Unit (CBM) | 0.26 m³ | 0.074 m³ | 71.5% reduction in space |
| 40HQ Container Capacity | 260 units | 925 units | +665 chairs per container |
Packaging & Shipping Metrics
Traditional Assembled Mode
M+ Modular KD Mode
Logistical Efficiency Gain
Packaging Density
1 chair per carton
5 chairs per carton
5x density increase
Volume per Unit (CBM)
0.26 m³
0.074 m³
71.5% reduction in space
40HQ Container Capacity
260 units
925 units
+665 chairs per container
Financial Insight: An order of 925 units fits into a single 40HQ container in the modular format. Shipped pre-assembled, the same order would need four containers (925 divided by 260 rounds up to 4). That's three fewer ocean freight containers for an order of this size. The same space savings carry over to the warehouse: since each component takes up 71.5% less volume than its assembled equivalent, distributors can hold the same range of styles in a much smaller footprint.
Precision Manufacturing, and Where M+ Stops
"A modular seating system lives or dies on manufacturing execution," notes Jie Zhang, Yumeya Furniture's Head of Product Engineering. "If a component varies by even half a millimeter, the entire chair becomes unassemblable in the field. Our manufacturing facility relies on high-precision calibration to guarantee a seamless, flush fit. A distributor's warehouse team simply tightens a few structural screws, and a commercial-grade, rock-solid chair is ready for delivery in minutes."
This precision ensures that while the M+ system offers the logistical benefits of a knock-down format, it delivers the uncompromising structural integrity of a traditionally welded frame. The engineered interlocking architecture is built specifically to withstand the rigorous, high-frequency daily use required in premium hospitality and senior living environments, backed by Yumeya's signature 10-year structural warranty.
About Yumeya Furniture
Yumeya Furniture has been working in commercial seating for nearly three decades and now operates in more than 80 countries and regions. The company pioneered commercial metal wood grain technology and backs its hospitality and senior living furniture with a 10-year structural warranty under a $0 after-sales cost policy. Yumeya partners with commercial furniture distributors worldwide who need seating that looks the part in high-end interiors and holds up under daily commercial use. For more information, please visit: https://www.yumeyafurniture.com/
Media Contact:
Company: Heshan Yumeya Furniture Co., Ltd
Website: https://www.yumeyafurniture.com/
Email: info@youmeiya.net
Whatsapp: +86 15219693331
Address: Zhennan Industry, Heshan City, Guangdong Province, China.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Yumeya Furniture Launches M+ Modular Seating to Solve Inventory and Freight Challenges in Commercial Hospitality and Senior Living Furniture
SAN DIEGO, July 14, 2026 /PRNewswire/ -- Ahead of the BIO International Convention, BIOSeedin Summer Innovation Partnering Summit was successfully held at Wyndham San Diego Bayside, California. Hosted by bioSeedin, the summit's discussion topics were about early-stage innovation assets, late-stage clinical pipelines, business development strategies, M&A trends, multinational collaboration models, and global licensing transactions.
ACROBiosystems participated as a key strategic partner under the theme "Enabling Global Opportunity," working with a broad network of industry partners to build a strategic partnering platform for the globalization of innovation assets. The event gathered more than 200 participants from over 30 countries, creating a highly active environment for business dialogue and partnering discussions.
During the summit, ACROBiosystems set up a dedicated networking lounge to provide attendees with an exclusive space for in-depth discussion, helping turn thought leadership and ideas into tangible collaboration.
As innovative drug development becomes increasingly global, ACROBiosystems is further leveraging its global customer network, technical service capabilities, industry insight, and ecosystem connectivity to advance its role as a global strategic partner for innovation. Through the summit, ACROBiosystems aims to amplify the visibility of high-potential innovation assets and help them gain greater international recognition, deeper industry understanding, and more partnering opportunities during a critical window for the global biopharmaceutical industry.
From winter to summer, ACROBiosystems has continued to advance global innovation partnerships. Following the BIOSeedin Winter Innovation Partnering Summit in San Francisco this January and the BIOSeedin Spring Innovation Partnering Summit in Shanghai this May, the BIOSeedin Summer Innovation Partnering Summit in San Diego further extended this momentum. Besides, ACROBiosystems has also hosted ACRO Innovation Day and the ACRO Innovation Forum in Europe and Shanghai, reinforcing its commitment to empowering the industry and building platforms for innovation exchange.
Looking ahead, ACROBiosystems will continue to work with global partners around its core brand values of "Reliable Quality, Integrated Innovation, and Considerate Service", jointly accelerating the translation of biopharmaceutical innovation into clinical applications and global markets.
Summit Recap
The summit opened with remarks from Ms. Jenny Zhao, Co-founder and CEO of bioSeedin.
And then the summit went on with panels and company presentations, along with one on one partnering session to motivate exchange and precision collaborations.
The panel session split into two parts: the early-stage and late-stage session.
No. 1 Early-Stage Session
The Early-Stage Session featured two panel discussions on licensing, external innovation, and M&A. The first panel brought together executives from Debiopharm, Otsuka Pharmaceutical, Roche/Genentech, AstraZeneca.
Key Takeaways:
- Licensing is not simply an asset transaction, but a strategic tool for translating differentiated science into long-term value.
- Strong biology, high-quality data, translational continuity, and a credible global clinical development plan remain essential to deal execution.
- Deals often stall due to weak biological rationale, unclear patient or biomarker strategies, poor PK/PD or therapeutic windows, and inadequate global development planning.
The second panel was moderated by Kenneth C. Chen, Senior Director of Business Development, US & EU, at bioSeedin, and featured executives from Sun Pharma, Hygieia Pharma, and Servier.
Key Takeaways:
- M&A should support long-term corporate strategy rather than serve as an end goal.
- Companies need to balance acquisitions, strategic investments, and licensing transactions.
- Successful M&A depends on valuation discipline, rigorous due diligence, effective execution, and post-deal integration.
The session also included company presentations from Antengene, GeneScience Pharmaceutical, and Salsola Therapeutics, showcasing innovative pipelines across autoimmune diseases, immunology, and neuropsychiatric disorders.
No. 2 Late-Stage Session
The Late-Stage Session Executives from Daiichi Sankyo, Takeda, Boehringer Ingelheim, and Thermo Fisher Scientific discussed the global innovation ecosystem and emerging industry trends.
Key Takeaways:
Innovation must remain grounded in strong science, robust biology, high-quality data, and rigorous R&D.
China and AI are long-term structural forces rather than short-term trends. Companies need a clear and coherent China strategy.
AI can support the full R&D value chain, but it cannot replace scientific fundamentals.
The session also featured presentations from HighTide Therapeutics, Constimulus Bio, CanWell Pharma, Jiangsu Chia Tai Fenghai Pharmaceutical, Amphiprotech, and VyBio, showcasing advanced pipelines and global development opportunities across multiple therapeutic areas.
About ACROBiosystems Group:
ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models. The company spans across the globe and maintains offices, R&D centers, and production bases in more than 15 different cities within the United States, Switzerland, the United Kingdom and Germany. ACROBiosystems Group has established numerous long-term and stable partnerships with the world's top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics.
ACROBiosystems' brands include Resilient Supply, CytoPak, SAFENSURE, FLAG, Star Staining, Aneuro, ComboX, GENPower and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.
Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and their clinical applications, and contributes to global health.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Converging at BIO, ACROBiosystems Connects Emerging Innovation Assets with Global Strategic Opportunities
